INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.25 USD | -0.10% |
|
-0.26% | -8.82% |
| May. 23 | Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target | MT |
| May. 21 | Incyte Acquires 2 Office Buildings in Delaware | MT |
ETFs positioned on Incyte Corporation
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 45 M€ | 0.00% | - | |
| 0.02% | 306 M€ | +6.11% | - | |
| 0.02% | 39 M€ | +6.07% | - | |
| 0.01% | 105 M€ | +3.68% | - | |
| 0.01% | 12 M€ | +16.96% | - | |
| 0.01% | 17 M€ | +2.99% | - | |
| 0.01% | 17 M€ | +5.25% | - | |
| 0.01% | 1 M€ | -.--% | ||
| 0.01% | 32 M€ | +1.29% | - | |
| 0.01% | 322 M€ | +13.88% | - | |
| 0.01% | 29 M€ | -.--% | - | |
| 0.01% | 34 M€ | +4.49% | - | |
| 0.01% | 54 M€ | +0.64% | - | |
| 0.01% | 6 M€ | +3.89% | ||
| 0.01% | 8 M€ | +0.90% | - | |
| 0.01% | 2 M€ | +3.16% | - | |
| 0.01% | 414 M€ | +12.77% | - | |
| 0.01% | 1,006 M€ | -.--% | - | |
| 0.01% | 756 M€ | -0.19% | - | |
| 1.20% | 129 M€ | +7.99% | - |
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
2024-06-10
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
57.25
USD
Average target price
72.8
USD
Spread / Average Target
+27.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.82% | 12.89B | |
| -2.60% | 90.28B | |
| -1.97% | 39.5B | |
| -15.47% | 31.71B | |
| +61.28% | 26.41B | |
| -22.81% | 14.34B | |
| -11.77% | 11.8B | |
| -45.97% | 10.95B | |
| +3.30% | 8.85B | |
| -17.43% | 7.53B |
- Stock Market
- Equities
- INCY Stock
- Funds and ETFs Incyte Corporation
